LCM
TBPH icon

Landscape Capital Management’s Theravance Biopharma TBPH Stock Holding History

Landscape Capital Management’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-11,216
Closed -$313K – 663
2017
Q4 		$313K Buy
+11,216
New +$332K 0.03% 478

Other funds holding TBPH

WIM
Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Landscape Capital Management's TBPH Position: Q1 2018 in Review

Landscape Capital Management sold out of Theravance Biopharma (TBPH) in Q1 2018, closing a stake of 11,216 shares — an estimated $313K sold.

Landscape Capital Management first reported a position in TBPH in Q4 2017 and held it in 1 quarter. The position peaked at $313K in Q4 2017. 90 funds tracked by Wall St. Rank hold TBPH as of Q1 2018.

  • Landscape Capital Management reported no remaining Theravance Biopharma position as of Q1 2018 after selling out during the quarter.
  • Landscape Capital Management sold 11,216 Theravance Biopharma shares in Q1 2018, an estimated $313K.
  • Landscape Capital Management first reported a position in Theravance Biopharma in Q4 2017 and held it in 1 quarter.
  • Landscape Capital Management's Theravance Biopharma position peaked at $313K in Q4 2017.
  • 90 funds tracked by Wall St. Rank held Theravance Biopharma as of Q1 2018.

Based on Landscape Capital Management's 13F filing for Q1 2018, filed 11 May 2018.